Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medication safety

Safety data prompt calls for a halt on NSAID use in patients with heart disease

Research has found that patients receiving antithrombotic therapy after myocardial infarction have twice the risk of further heart attacks if they take nonsteroidal anti-inflammatory drugs.

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients receiving antithrombotic therapy after myocardial infarction (MI) doubles the risk of further heart attacks. In the image, scan of a heart attack.

Source: Zephyr / Science Photo Library

Patients receiving antithrombotic therapy after myocardial infarction have twice the risk of another heart attack (pictured as a scan) if they take nonsteroidal anti-inflammatories

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients receiving antithrombotic therapy after myocardial infarction (MI) doubles the risk of further heart attacks and significantly increases the risk of other thrombotic events and serious bleeding compared with those who do not receive NSAIDs, according to a study published in JAMA[1].

At first sight, the study appears only to confirm a widespread growing awareness of the cardiovascular (CV) toxicity of many NSAIDs, but the new insight – regarding the risk levels associated with even minimal treatment durations and dosage levels, for example – provides new grounds for concern.

The findings have prompted calls for heightened caution when prescribing NSAIDs, or even a complete halt on their use pending better understanding of the mechanisms involved across different patient groups and therapy combinations.

Using data obtained from Danish national registries, the study considered a population of 61,971 patients aged 30 years or over who were admitted with first-time MI and who lived at least 30 days after discharge, out of a total of 88,662 patients admitted with first-time MI during a period spanning 2002-2011.

The study measured the risk of bleeding (requiring admission to hospital) or of a composite CV outcome (CV death, recurrent MI, ischaemic stroke, transient ischaemic attack or systemic arterial emboli) in relation to combinations of NSAID and anticoagulant therapies. The latter consisted of aspirin, clopidogrel or vitamin K antagonist, or combinations of these. NSAIDs were categorised as follows: rofecoxib and celecoxib as ‘selective COX-2 inhibitors’; ibuprofen, diclofenac and naproxen as ‘nonselective NSAIDs’; and ‘other NSAIDs’.

Of the almost 62,000 patients studied, 34% were prescribed at least one NSAID. The median follow-up spanned 3.5 years, during which time there were 18,105 deaths (29.2%). The study recorded 5,288 bleeding events (8.5%), of which 15% (799) were fatal, and 18,568 (30.0%) CV events. Using regression analysis, the team calculated hazard ratios of 2.02 and 1.40, respectively, involving concomitant NSAID treatment (compared with no use of NSAIDs).

In the discussion, noting that “in many countries ibuprofen is available without prescription in pharmacies and retail outlets, with few restrictions on the amounts that may be purchased”, the team explains that the increased risks “were evident regardless of antithrombotic treatment, types of NSAIDs or duration of use. No safe treatment period exists”.

The team concludes that, while “more research is needed to confirm these findings, physicians should exercise appropriate caution when prescribing NSAIDs for patients who have recently experienced MI”.

In an accompanying JAMA editorial[2], cardiologists Charles Campbell and David Moliterno went further: “Practitioners would do well to advise patients with cardiovascular disease against all NSAID use (except low-dose aspirin), especially patients with a recent acute coronary syndrome”, pending the results of the large PRECISION (prospective randomised evaluation of celecoxib integrated safety vs ibuprofen or naproxen) trial, expected within the next year.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20067994

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.